by barry101 | Jan 7, 2021 | Press Releases
HOUSTON, Jan. 7, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of...
by barry101 | Dec 29, 2020 | Press Releases
HOUSTON, Dec. 29, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and...
by barry101 | Dec 17, 2020 | Press Releases
HOUSTON, Dec. 17, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and...
by barry101 | Dec 3, 2020 | Press Releases
HOUSTON, Dec. 3, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present...
by barry101 | Dec 1, 2020 | Press Releases
Priority Review Vouchers subject to approved NDAHOUSTON, Dec. 1, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and...
by barry101 | Nov 19, 2020 | Press Releases
Experimental data to be presented at American Society for Hematology Annual ConferenceHOUSTON, Nov. 19, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
